Menu
Not yet recruiting NCT07106450

Training Induced Muscle-Adipose EV Communication

No phase Interventional Prediabetes

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acute Resistance Exercise.
Who it may be relevant to
Registry conditions: Prediabetes. Basic parameters: 30 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Muscle-derived Extracellular Vesicles and Their Interactions With Adipocytes in Human Metabolic Dysfunction

Overview

This study examines how muscle cells communicate with fat cells through tiny packages called extracellular vesicles (EV) during exercise. These vesicles carry important molecules that may affect how the body processes sugar and fat. The research team observed significant variability in the adipose response to exercise, and used this variability to gain further insight into the mechanism through which mature microRNA-1 (miR-1) changes in adipose tissue. The investigators selected six subjects with the highest increase in miR-1 abundance in adipose tissue after exercise and compared them with the six subjects that had the most dramatic decrease in miR-1 abundance after exercise. The research team observed that participants intrinsically vary in their ability to endocytose EV into adipose tissue. It is unclear whether this variance in receptivity is a cause or consequence of the significant difference in EV-delivery of miR-1 to adipose tissue.

Detailed description

This study investigates muscle-derived extracellular vesicle (EV) communication with adipose tissue and how this pathway is altered in pre-diabetes. The investigators will recruit 40 participants (20 euglycemic controls, 20 pre-diabetic) aged 30-55 years, equally distributed by sex. Pre-diabetes will be defined as impaired fasting glucose (100-125 mg/dL), impaired glucose tolerance (2-hour oral glucose tolerance test (OGTT) 140-199 mg/dL), or HbA1C 5.7-6.4%.

Following informed consent and medical screening at the Center for Clinical and Translational Sciences, participants will undergo baseline blood draw and tissue biopsies (subcutaneous adipose and vastus lateralis muscle) one hour prior to exercise. The resistance exercise protocol consists of whole-body resistance training at 80% 1RM (repetition maximum) intensity including bench press, leg press, and pull-downs. Blood samples will be collected immediately post-exercise and at 30, 60, and 90 minutes. Post-exercise biopsies will be obtained approximately 60 minutes after exercise cessation.

Laboratory analyses will include: (1) microRNA-1 (miR-1) quantification in adipose tissue by quantitative reverse transcription polymerase chain reaction (qRT-PCR) as the primary validated outcome of EV uptake; (2) fluorescently-labeled EV uptake assessment in cultured adipocytes using microscopy; (3) RNA sequencing (RNA-seq) of adipose tissue to identify transcriptomic signatures associated with EV uptake capacity; (4) primary cell culture studies using adult-derived human adipocyte stem cells (ADHASC); and (5) EV isolation and characterization using size exclusion chromatography and density gradient centrifugation.

Interventions

  • Behavioral Acute Resistance Exercise
    Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).

Primary outcome measures

  • miR-1 abundance in adipose tissue [Time frame: 60 minutes post-exercise (single measurement)]
  • Extracellular vesicle uptake capacity in primary adipocytes [Time frame: 24-48 hours post-isolation (in vitro culture)]
Secondary outcome measures (4)
  • Serum extracellular vesicle miR-1 content [Time frame: Baseline, 0, 30, 60, and 90 minutes post-exercise]
  • Adipose tissue transcriptomic signatures [Time frame: 60 minutes post-exercise (single measurement)]
  • Adrenergic receptor gene expression in adipose tissue [Time frame: 60 minutes post-exercise (single measurement)]
  • Primary muscle miR-1 transcript levels [Time frame: 60 minutes post-exercise (single measurement)]

Eligibility criteria

Inclusion criteria

  • Age 30-55 years
  • Sedentary lifestyle (exercise <1 day/week for at least 3 months prior to enrollment)
  • Able to provide informed consent
  • For Control Group: BMI < 27 kg/m², normal glucose tolerance, no more than 1 feature of metabolic syndrome
  • For Prediabetic Group: BMI > 30 kg/m², at least 3 features of metabolic syndrome including prediabetes (defined as fasting plasma glucose 100-125 mg/dL OR 2-hour post-load glucose on 75g OGTT 140-199 mg/dL OR HbA1C 5.7-6.4%)

Exclusion criteria

  • Pregnancy (confirmed by pregnancy test in women of childbearing potential)
  • Type 2 diabetes mellitus
  • Cardiovascular contraindications to resistance exercise
  • Medical conditions that would interfere with muscle or adipose tissue biopsy procedures
  • Use of medications that significantly affect glucose metabolism or exercise response
  • Active participation in structured exercise programs (>1 day/week) within 3 months of enrollment
  • Inability to safely participate in resistance exercise protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Kentucky — Lexington

Identifiers

NCT: NCT07106450 · P20GM156679-Prj5 · P20GM156679

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗